

**Losartan Formulation**

Version 6.2      Revision Date: 2025/07/01      SDS Number: 300000000861      Date of last issue: 2023/09/26  
Date of first issue: 2014/10/07

---

**SECTION 1. IDENTIFICATION**

Product identifier : Losartan Formulation

**Manufacturer or supplier's details**

Company : Organon & Co.

Address : Rua Treze de Maio, 1161  
Campinas, São Paulo, Brazil 13106-054

Telephone : +1 551-430-6000 US | +55 (19) 3758-2000 BR

Emergency telephone : For 24/7 emergency response advice, call CHEMTREC at +55 11 4349-1359 (local) or 0800 892 0479 (toll-free). Global 24/7: +1-800-424-9300 (United States, English only).

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification in accordance with ABNT NBR 14725 Standard**

Acute toxicity (Oral) : Category 4

Serious eye damage : Category 1

Skin sensitization : Category 1

Reproductive toxicity : Category 1B

Effects on or via lactation

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)

**GHS label elements in accordance with ABNT NBR 14725 Standard**

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H302 Harmful if swallowed.  
H317 May cause an allergic skin reaction.  
H318 Causes serious eye damage.  
H360D May damage the unborn child.

---

## Losartan Formulation

Version 6.2      Revision Date: 2025/07/01      SDS Number: 300000000861      Date of last issue: 2023/09/26  
 Date of first issue: 2014/10/07

H362 May cause harm to breast-fed children.  
 H373 May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

## Precautionary Statements

:

**Prevention:**

P201 Obtain special instructions before use.  
 P260 Do not breathe dust.  
 P263 Avoid contact during pregnancy and while nursing.  
 P264 Wash skin thoroughly after handling.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.  
 P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.  
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Contact with dust can cause mechanical irritation or drying of the skin.  
 May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Cellulose	9004-34-6		>= 30 -< 50
Losartan Potassium	124750-99-8	Acute Tox. (Oral), 4 Eye Dam., 1 Skin Sens., 1 Repr., 1B Lact. STOT RE, (Oral)(Blood, Cardio-vascular system, Stomach, Kidney) , 2	>= 30 -< 50
Starch	9005-25-8		>= 10 -< 20

## Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

### SECTION 4. FIRST AID MEASURES

- |   |   |  |
|---|---|--|
| General advice  | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.   |
| If inhaled  | : | If inhaled, remove to fresh air.<br>Get medical attention.   |
| In case of skin contact                                     | : | In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse.  |
| In case of eye contact                                      | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.<br>If easy to do, remove contact lens, if worn.<br>Get medical attention immediately.   |
| If swallowed  | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.<br>Never give anything by mouth to an unconscious person.  |
| Most important symptoms and effects, both acute and delayed | : | Contact with dust can cause mechanical irritation or drying of the skin.<br>Harmful if swallowed.<br>May cause an allergic skin reaction.<br>Causes serious eye damage.<br>May damage the unborn child.<br>May cause harm to breast-fed children.<br>May cause damage to organs through prolonged or repeated exposure if swallowed. |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  |
| Notes to physician  | : | Treat symptomatically and supportively.  |
- 

### SECTION 5. FIRE-FIGHTING MEASURES

- |                                       |   |   |
|---------------------------------------|---|---|
| Suitable extinguishing media          | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media        | : | None known.   |
| Specific hazards during fire fighting | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products         | : | Carbon oxides<br>Nitrogen oxides (NO <sub>x</sub> )   |

## Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

Chlorine compounds

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Avoid contact during pregnancy and while nursing.  
Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.

---

## Losartan Formulation

Version 6.2      Revision Date: 2025/07/01      SDS Number: 300000000861      Date of last issue: 2023/09/26  
 Date of first issue: 2014/10/07

- Do not get in eyes.  
 Wash skin thoroughly after handling.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Do not eat, drink or smoke when using this product.  
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Contaminated work clothing should not be allowed out of the workplace.
- Conditions for safe storage : Wash contaminated clothing before re-use.  
 Keep in properly labeled containers.  
 Store locked up.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Self-reactive substances and mixtures  
 Organic peroxides  
 Explosives  
 Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Losartan Potassium	124750-99-8	TWA	100 µg/m <sup>3</sup> (OEB 2)	Internal
Starch	9005-25-8	TWA	10 mg/m <sup>3</sup>	ACGIH

- Engineering measures** : Minimize workplace exposure concentrations.  
 Apply measures to prevent dust explosions.  
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).  
 If sufficient ventilation is unavailable, use with local exhaust ventilation.

## Personal protective equipment

## Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type  
Use respiratory protection unless adequate local exhaust ventilation is provided or exposure assessment demonstrates that exposures are within recommended exposure guidelines.  
Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
- Eye protection : Wear the following personal protective equipment:  
Chemical resistant goggles must be worn.  
If splashes are likely to occur, wear:  
Face-shield
- Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.  
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Physical state : powder
- Color : White to light yellow
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : No data available
- Evaporation rate : No data available
- Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

**Losartan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	1 g/cm <sup>3</sup>
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Minimum ignition energy	:	> 300 mJ
Particle characteristics Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents

**Losartan Formulation**

Version 6.2      Revision Date: 2025/07/01      SDS Number: 300000000861      Date of last issue: 2023/09/26  
Date of first issue: 2014/10/07

---

Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Harmful if swallowed.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 1.502 mg/kg  
Method: Calculation method

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

**Losartan Potassium:**

Acute oral toxicity : LD50 (Mouse): 1.257 - 1.590 mg/kg

LDLo (Rat): 200 mg/kg

LDLo (Mouse): 400 mg/kg

**Starch:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

**Skin corrosion/irritation**

Based on available data, the classification criteria are not met.

**Components:****Losartan Potassium:**

Species : Rabbit  
Result : Mild skin irritation

**Serious eye damage/eye irritation**

Causes serious eye damage.

**Losartan Formulation**

Version 6.2      Revision Date: 2025/07/01      SDS Number: 300000000861      Date of last issue: 2023/09/26  
Date of first issue: 2014/10/07

---

**Components:****Losartan Potassium:**

Species : Rabbit  
Result : Severe irritation

**Starch:**

Species : Rabbit  
Result : No eye irritation

**Respiratory or skin sensitization****Skin sensitization**

May cause an allergic skin reaction.

**Respiratory sensitization**

Based on available data, the classification criteria are not met.

**Components:****Losartan Potassium:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Assessment : Probability or evidence of skin sensitization in humans  
Result : positive

Test Type : Respiratory sensitization  
Remarks : No data available

**Starch:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

**Germ cell mutagenicity**

Based on available data, the classification criteria are not met.

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay  
Result: negative  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse

## Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

Application Route: Ingestion  
Result: negative

### Losartan Potassium:

Genotoxicity in vitro : Test Type: in vitro test  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay  
Result: negative

### Carcinogenicity

Based on available data, the classification criteria are not met.

### Components:

#### Cellulose:

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

#### Losartan Potassium:

Species : Mouse  
Application Route : Oral  
Exposure time : 92 weeks  
Dose : 200 mg/kg body weight  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 105 weeks  
Dose : 270 mg/kg body weight  
Result : negative

## Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

### Reproductive toxicity

May damage the unborn child.  
May cause harm to breast-fed children.

### Components:

#### Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

#### Losartan Potassium:

Effects on fertility : Test Type: Fertility  
Species: Rat, female  
Application Route: Oral  
Fertility: LOAEL: 200 mg/kg body weight  
Result: female reproductive effects  
Remarks: Maternal toxicity observed.

Effects on fetal development : Test Type: Development  
Species: Rabbit  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 10 mg/kg body weight  
Developmental Toxicity: NOAEL F1: 20 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, No teratogenic effects.

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: Fetotoxicity., No teratogenic effects.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Studies indicating a hazard to babies during the lactation period

### STOT-single exposure

Based on available data, the classification criteria are not met.

## Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

### Components:

#### Losartan Potassium:

Remarks : Not classified

#### STOT-repeated exposure

May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

### Components:

#### Losartan Potassium:

Routes of exposure : Ingestion  
 Target Organs : Blood, Cardio-vascular system, Stomach, Kidney  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

#### Repeated dose toxicity

### Components:

#### Cellulose:

Species : Rat  
 NOAEL :  $\geq 9.000$  mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days

#### Losartan Potassium:

Species : Rat  
 LOAEL : 15 mg/kg  
 Application Route : Oral  
 Exposure time : 309 d  
 Number of exposures : daily  
 Target Organs : Blood, Kidney, Cardio-vascular system, Stomach

Species : Dog  
 NOAEL : 5 mg/kg  
 Application Route : Oral  
 Exposure time : 1 Months  
 Symptoms : Salivation, Vomiting

Species : Dog  
 LOAEL : 25 mg/kg  
 Application Route : Oral  
 Exposure time : 53 Weeks  
 Number of exposures : daily  
 Symptoms : Salivation, Vomiting

#### Starch:

Species : Rat  
 NOAEL :  $\geq 2.000$  mg/kg

**Losartan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

**Aspiration toxicity**

Based on available data, the classification criteria are not met.

**Components:****Losartan Potassium:**

Not applicable

**Experience with human exposure****Components:****Losartan Potassium:**

Eye contact : Symptoms: Eye irritation  
Ingestion : Symptoms: hypotension, tachycardia

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
Exposure time: 96 h  
Remarks: Based on data from similar materials

**Ecotoxicology Assessment**

Acute aquatic toxicity : No toxicity at the limit of solubility.

**Losartan Potassium:**

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): > 929 mg/l  
Exposure time: 96 h  
Method: FDA 4.11

Toxicity to daphnia and other : EC50 (*Daphnia magna* (Water flea)): 331 mg/l  
aquatic invertebrates : Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic : NOEC (*Microcystis aeruginosa* (blue-green algae)): 949 mg/l  
plants : Exposure time: 10 d  
Method: FDA 4.01

NOEC (*Selenastrum capricornutum* (green algae)): 143 mg/l  
Exposure time: 10 d  
Method: FDA 4.01

## Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 10 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 100 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

### Persistence and degradability

#### Components:

##### **Cellulose:**

Biodegradability : Result: Readily biodegradable.

##### **Losartan Potassium:**

Biodegradability : Result: Not biodegradable  
Biodegradation: 71 %  
Exposure time: 28 d

Stability in water : Hydrolysis: < 10 %(5 d)

### Bioaccumulative potential

#### Components:

##### **Losartan Potassium:**

Partition coefficient: n-octanol/water : log Pow: 1,2

##### **Mobility in soil**

No data available

##### **Other adverse effects**

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### **International Regulations**

#### **UNRTDG**

Not regulated as a dangerous good

---

**Losartan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****ANTT**

Not regulated as a dangerous good

**Special precautions for user**

Not applicable

---

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**National List of Carcinogenic Agents for Humans - : Not applicable  
(LINACH)Brazil. List of chemicals controlled by the Federal Po- : Not applicable  
lice**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**SECTION 16. OTHER INFORMATION**Revision Date : 2025/07/01  
Date format : yyyy/mm/dd**Further information**Sources of key data used to : Internal technical data, data from raw material SDSs, OECD  
compile the Material Safety eChem Portal search results and European Chemicals Agen-  
Data Sheet cy, <http://echa.europa.eu/>**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

## Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
6.2	2025/07/01	300000000861	Date of first issue: 2014/10/07

---

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

BR / EN